Bayer announced it would stop selling its Essure birth control device at the end of 2018. It’s the end of the device in the U.S., but it may only be the beginning of more controversy surrounding the implant.
Bayer insists its decision to discontinue Essure was a financial decision. It blames “misleading and inaccurate publicity” for plummeting sales.
But the U.S. Food and Drug Administration tied the decrease in sales to regulatory actions. Safety concerns led the FDA to place a black box warning on the device and restrict its sales.